Brought to you by 
Pfizer adds to rare disease pipeline with worldwide rights to Opko's growth hormone
21 Oct 2019
Executive Summary
Opko Health Inc. licensed Pfizer Inc. exclusive global rights to commercialize long-acting recombinant human growth hormone Lagova (hGH-CTP), which is in Phase III for growth hormone deficiency (GHD) in adults and Phase II for pediatric patients. The compound is also in development for treating growth failure in children born small for gestational age (SGA) who don’t catch up in growth by age two.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer adds to rare disease pipeline with worldwide rights to Opko's growth hormone
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice